the core of our corporate values
Hangzhou, China, 29 November 2021- Zylox-Tonbridge (2190.HK, the “Company”) announced the last patient enrollment was completed for the clinical trial of “Tonbridge KylinTM” Flow Diverter (single ...
On November 16, 2021, Zylox-Tonbridge (2190.HK) successfully held the first Investor Day Event at its Hangzhou Headquarter. The event brought together more than 100 institutional investors and securit...
At the recent 2021 Oriental Conference of Interventional Neuroradiology (OCIN2021), Tonbridge Medical, the Neuro-intervention Business Division of Zylox-Tonbridge, successfully held the national launc...
Hangzhou, China, 15 November 2021- Zylox-Tonbridge (2190.HK, the "Company") announced the Company has signed a collaboration agreement with Sky Road. Under the agreement, Sky Road has grante...
On September 27th, Zylox-Tonbridge (2190.HK), one of the leading players in neuro- and peripheral- interventional medical device market in China, announced that the neurovascular embolization coils in...
On September 23, Zylox-Tonbridge announced that the Shareholders’ Meeting has approved the H-share incentive trust scheme proposed by its Board of Directors. The trust scheme is intended to give equi...